You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥及疫苗股受捧 國藥(01099.HK)及復星醫藥(02196.HK)續升8%及20%
阿思達克 05-10 09:59
新冠疫苗股今早全面跑贏,尤其是復星醫藥(02196.HK)回落收市始終守穩20天線,今早延續上周五彈勢,突破10天線(51.36元)後,升幅擴大,最高見61.35元,暫受制上周二盤中所創紀錄高位62.5元,現造59.95元,急漲20%,成交已達1,539萬股。復星醫藥公布,與BioNTech訂立協議,為新冠疫苗產品本地化生產和商業化設立一家合營各持一半權益,復星出資不超1億美元,另公司會再對合營提供不超1.5億歐元股東貸款及為合營銀行融資提供支持。

世衛總幹事譚德塞表示,將國藥新冠疫苗列入世衛緊急使用清單。國藥控股(01099.HK)承上周五升勢,今早股價升破10天線(24.9元),最高見27.2元,暫受制上周二盤中所創逾一年高位27.6元,現造26.15元,續升8%,成交已達1,009萬股。

康希諾生物-B(06185.HK)扭五連跌,今早股價重越50天線(317.4元),最高見329.8元,現造321.8元,回升6%。開拓藥業-B(09939.HK)扭四連跌,今早股價曾重越10天線(69元),最高見70.85元,現造67.5元,回升7.1%。

內地第五批藥品集採今天(10日)起開始信息申報,涉及202個品規。藥明康德(02359.HK)、藍籌石藥(01093.HK)、藥明生物(02269.HK)及中生製藥(01177.HK)依次升2%-4.5%,後者最強,股價一舉重越10天、20天及50天線曾高見8.42元。四環醫藥(00460.HK)扭三連跌,高見2.87元,現造2.81元,回升4.9%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account